RAZA SAIYED ATIQ 4

What Happened
Raza Saiyed Atiq, a director of Arteris, sold a total of 90,000 shares in two open‑market transactions: 72,940 shares on 2026-04-17 for reported proceeds of $1,616,270 (weighted avg $22.16; prices in that block ranged $22.00–$22.46) and 17,060 shares on 2026-04-20 for reported proceeds of $378,084 (weighted avg $22.16; prices in that block ranged $22.05–$22.24). Total proceeds were approximately $1,994,354. These were sales (not purchases) and therefore typically represent routine dispositions rather than an acquisition signal.

Key Details

• Transaction dates: 2026-04-17 (72,940 shares) and 2026-04-20 (17,060 shares).
• Reported weighted average price on each line: $22.16; per-footnote price ranges: $22.00–$22.46 (Apr 17 block) and $22.05–$22.24 (Apr 20 block).
• Total shares sold: 90,000; total reported proceeds: ~$1.99M.
• Shares held after the transactions: not stated in the filing.
• Footnotes of note: F1 — sales were made pursuant to a 10b5‑1 trading plan adopted Nov 7, 2025; F3 — shares were held in the "Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust" for which he is trustee; F2/F4 — the prices shown are weighted averages across multiple execution prices (details available on request).
• Filing date: Form 4 filed 2026-04-21. The report appears to be filed within the normal SEC Form 4 timing window for the listed transaction dates.

Context
Sales executed under a 10b5‑1 plan are pre‑scheduled trades made according to a written plan and are commonly used by insiders to avoid questions about timing; they do not necessarily reflect a change in personal view about the company. As with all insider sales, retail investors should view this as a disclosure of liquidity rather than a definitive signal about future company performance.